跳至主要内容
临床试验/IRCT20211202053252N1
IRCT20211202053252N1已完成3 期

Comparison of recombinant erythropoietin effect on serum hemoglobin of beta thalassemia minor versus non-thalassemia patients in chemotherapy candidates

Babol University of Medical Sciences0 个研究点目标入组 72 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
72

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 no limit(—)
性别
All

入选标准

  • Aged over 18 years old
  • Metastatic cancer patients on first-line chemotherapy plan
  • Patients with visceral(confirmed with CT scan or MRI) or/and bone(less than 5-confirmed with bone scintigraphy) metastases
  • Initial serum hemoglobin less than 13 g/d

排除标准

  • Leukemia/Plasma cell dyscrasia
  • Less than 3 months life expectancy
  • Major and intermedia thalassemia based on hemoglobin electrophoresis
  • Patients at risk for vascular thromboembolism(e.g. history of venous thromboembolism or ischemic stroke, patients with metallic prostheses in heart or vessels(excluding coronary stents after one year of placement)
  • Taking drugs which effect on estrogen/progesterone receptor or any other drug that raises risk of thromboembolism during chemotherapy
  • Uncontrolled high blood pressure(systolic BP over 160mmHg or diastolic BP over 95mmHg in three visits within a month despite treatment)
  • A history of taking therapeutic radiopharmaceuticals in past three months
  • A history of blood transfusion within three months before trial initiation

研究者

相似试验